ICU Medical (ICUI) Projected to Post Quarterly Earnings on Thursday

Key Points

• ICU Medical is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $1.44 per share and revenue of $543.33 million.
• The company's last earnings report showed strong performance with revenue of $599.49 million, surpassing analyst estimates and reflecting a 6.7% year-over-year increase.
• Recent insider activity includes significant stock sales by directors, with 1,942 shares sold by David C. Greenberg, reducing his holdings by 22.32%.

ICU Medical (NASDAQ:ICUI - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect ICU Medical to post earnings of $1.44 per share and revenue of $543.33 million for the quarter.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The firm had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. During the same quarter in the previous year, the firm posted $0.96 earnings per share. The business's revenue was up 6.7% on a year-over-year basis. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Down 0.8%

ICUI traded down $1.01 during trading on Friday, reaching $127.40. The company had a trading volume of 242,242 shares, compared to its average volume of 250,634. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. ICU Medical has a 12 month low of $117.92 and a 12 month high of $196.26. The business's fifty day moving average price is $130.65 and its 200 day moving average price is $141.97. The company has a market cap of $3.14 billion, a P/E ratio of -33.26 and a beta of 0.87.

Insider Buying and Selling at ICU Medical

In other news, Director Elisha W. Finney sold 600 shares of ICU Medical stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $138.92, for a total value of $83,352.00. Following the sale, the director directly owned 3,252 shares in the company, valued at $451,767.84. This trade represents a 15.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Greenberg sold 1,942 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total transaction of $278,987.72. Following the sale, the director directly owned 6,760 shares in the company, valued at $971,141.60. This trade represents a 22.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,097 shares of company stock valued at $4,860,156 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in ICU Medical by 32.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier's stock worth $9,472,000 after acquiring an additional 16,680 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier's stock worth $1,772,000 after acquiring an additional 560 shares in the last quarter. Intech Investment Management LLC raised its position in ICU Medical by 38.6% during the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier's stock worth $1,658,000 after acquiring an additional 3,326 shares in the last quarter. AQR Capital Management LLC raised its position in ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock worth $1,297,000 after acquiring an additional 229 shares in the last quarter. Finally, United Services Automobile Association bought a new stake in ICU Medical during the first quarter worth $218,000. 96.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on ICUI. KeyCorp cut their price target on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a report on Tuesday, April 8th. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday, May 18th. Finally, Raymond James Financial lowered their price objective on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.